← Back to Search

Dementia Home Care Intervention for Dementia

Richmond, VA
N/A
Waitlist Available
Led By Christine S Ritchie, MD, MSPH
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-intervention (6 months)
Awards & highlights
No Placebo-Only Group

Summary

This trial will develop an intervention to improve care for people living with dementia and their caregivers in home-based primary care practices.

Who is the study for?
This trial is for adult caregivers living in the U.S. who provide at least 4 hours of daily care to someone with Alzheimer's or related dementias and are experiencing stress. Participants must speak English and expect to continue caregiving for the next 6 months. Staff participants should be part of a home-based primary care program.
What is being tested?
The study aims to develop 'Dementia Care Quality at Home' for those with dementia and their caregivers, assessing its feasibility, acceptability, and fidelity within home-based primary care practices through an open-pilot trial involving trained clinicians.
What are the potential side effects?
Since this intervention focuses on caregiver support rather than medical treatment, traditional side effects are not applicable. However, there may be emotional or psychological impacts from participating in focus groups or implementing new care strategies.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-intervention (6 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and post-intervention (6 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility for the caregiver to access educational materials and community resources.
Feasibility for the caregiver to engage with and complete baseline assessments.
Feasibility for the practice of assessing eligible patient/caregiver dyads.
+2 more
Other study objectives
Acceptability of the intervention to caregivers and patient to participate in the intervention.
Caregiver well-being
Feasibility for the practice of clinicians to engage with the tele-video case conference.
+5 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dementia Care Quality at HomeExperimental Treatment1 Intervention
Each HBPC practice will receive the Dementia Care Quality at Home intervention.

Find a Location

Closest Location:Virginia Commonwealth University· Richmond, VA

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
3,061 Previous Clinical Trials
13,425,685 Total Patients Enrolled
26 Trials studying Dementia
202,627 Patients Enrolled for Dementia
Retirement Research FoundationOTHER
9 Previous Clinical Trials
1,706 Total Patients Enrolled
1 Trials studying Dementia
50 Patients Enrolled for Dementia
Christine S Ritchie, MD, MSPHPrincipal InvestigatorMassachusetts General Hospital
2 Previous Clinical Trials
524 Total Patients Enrolled
1 Trials studying Dementia
13 Patients Enrolled for Dementia
Bruce Leff, MDPrincipal InvestigatorJohns Hopkins University

Media Library

Dementia Care Quality at Home Clinical Trial Eligibility Overview. Trial Name: NCT05849259 — N/A
Dementia Research Study Groups: Dementia Care Quality at Home
Dementia Clinical Trial 2023: Dementia Care Quality at Home Highlights & Side Effects. Trial Name: NCT05849259 — N/A
Dementia Care Quality at Home 2023 Treatment Timeline for Medical Study. Trial Name: NCT05849259 — N/A
~40 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top